Detail akcie Omniab Rg online

Business Summary: OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, OmniAB Inc revenues decreased 34% to $10.3M. Net loss increased 3% to $50.6M. Revenues reflect Service revenue segment decrease of 46% to $5.1M, License and milestone revenue segment decrease of 26% to $3.9M. Higher net loss reflects Research and development - Balancing increase of 8% to $29.1M (expense), Other operating expense (income), net decrease of 68% to $747K (income).